According to a recent LinkedIn post from Circular Genomics, the company is highlighting a new publication in Nature Molecular Psychiatry that explores a brain-derived circular RNA biomarker tied to antidepressant response. The post describes research on CDR1as, a circRNA regulated by 5-HT2A and BDNF/TrkB signaling, which is presented as a specific predictor of SSRI treatment outcomes, particularly for sertraline.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that baseline levels of CDR1as may help distinguish future responders from non-responders to SSRIs with high accuracy, potentially reducing the trial-and-error process in depression treatment. For investors, this work points to continued progress in biomarker-driven, personalized psychiatry, which could enhance Circular Genomics’ technology pipeline and strengthen its positioning in the emerging pharmacogenomics and precision mental health markets.
If validated in larger clinical settings and translated into commercial diagnostics, such a biomarker could support new revenue streams through companion tests or decision-support tools for antidepressant selection. The association with a high-impact journal and emphasis on predictive accuracy may also improve the company’s visibility with partners, including pharmaceutical companies and providers, potentially influencing future collaborations, funding opportunities, and valuation expectations.